These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31652079)

  • 1. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    Expert Rev Clin Immunol; 2019 Dec; 15(12):1303-1312. PubMed ID: 31652079
    [No Abstract]   [Full Text] [Related]  

  • 2. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
    Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
    J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection.
    Caso F; Cantarini L; Morisco F; Del Puente A; Ramonda R; Fiocco U; Lubrano E; Peluso R; Caso P; Galeazzi M; Punzi L; Scarpa R; Costa L
    Expert Opin Biol Ther; 2015 May; 15(5):641-50. PubMed ID: 25652590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.
    Lubrano E; Perrotta FM
    Drugs; 2016 Apr; 76(6):663-73. PubMed ID: 26957495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.
    Palazzi C; D'Angelo S; Leccese P; Padula A; Olivieri I
    Expert Opin Drug Saf; 2014 Feb; 13(2):191-6. PubMed ID: 24219428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis.
    Esposito M; Carubbi F; Giunta A; Alunno A; Giacomelli R; Fargnoli MC
    Expert Rev Clin Immunol; 2020 Feb; 16(2):119-128. PubMed ID: 31917928
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.
    Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K
    J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
    Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
    J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
    Wong VK; Lebwohl MG
    Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriatic arthritis.
    Wollina U; Unger L; Heinig B; Kittner T
    Dermatol Ther; 2010; 23(2):123-36. PubMed ID: 20415819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis.
    Salvarani C; Olivieri I; Pipitone N; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M;
    Clin Exp Rheumatol; 2006; 24(1):70-8. PubMed ID: 16539822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-sectional multicenter observational study of psoriatic arthritis in Japanese patients: Relationship between skin and joint symptoms and results of treatment with tumor necrosis factor-α inhibitors.
    Tsuruta N; Narisawa Y; Imafuku S; Ito K; Yamaguchi K; Miyagi T; Takahashi K; Fukamatsu H; Morizane S; Koketsu H; Yamaguchi M; Hino R; Nakamura M; Ohyama B; Ohata C; Kuwashiro M; Sato T; Saito K; Kaneko S; Yonekura K; Hayashi H; Yanase T; Morimoto K; Sugita K; Yanagihara S; Kikuchi S; Mitoma C; Nakahara T; Furue M; Okazaki F
    J Dermatol; 2019 Mar; 46(3):193-198. PubMed ID: 30628100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistant cases of psoriatic arthritis: how to manage them.
    Atzeni F; Sarzi-Puttini P; Vena GA
    J Rheumatol Suppl; 2009 Aug; 83():73-5. PubMed ID: 19661549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.
    Weitz JE; Ritchlin CT
    Expert Opin Biol Ther; 2014 Apr; 14(4):515-26. PubMed ID: 24555741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor inhibitors in psoriatic arthritis.
    Mantravadi S; Ogdie A; Kraft WK
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):899-910. PubMed ID: 28490202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S; Thomas BJ; Ciurtin C
    Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.
    Saad AA; Hyrich KL; Ashcroft DM
    Expert Opin Drug Saf; 2011 Mar; 10(2):219-26. PubMed ID: 21208138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.